

Health Care Portfolio, Series 39

Investment Objective

The Health Care Portfolio, Series 39 (Trust) seeks to maximize total return through capital appreciation with a secondary objective of current income.

Key Considerations


- **Diversification:** The Trust seeks to provide concentrated exposure to the health care sector while remaining diversified across the following key industries: Biotechnology, Pharmaceuticals, Health Care Equipment & Supplies, Health Care Providers & Services, and Life Sciences Tools & Services.¹
- **Defensive Growth:** Health care is a defensive sector that offers services that consumers need regardless of business cycle and may be resistant to economic phases.
- **Innovations in Medicine:** Approximately 48% of the portfolio is invested in pharmaceuticals and biotechnology stocks that may offer high upside potential from medical breakthroughs.²

¹ Diversification neither assures a profit nor eliminates the risk of experiencing investment losses. ² FactSet, 7/15/2025.


PORTFOLIO ALLOCATION

Breakdowns and weighting are as of 7.16.2025 and subject to change.


CAPITALIZATION BREAKDOWN



STYLE BREAKDOWN



INDUSTRY BREAKDOWN




A Defensive Sector with Opportunity for Growth

The importance of the health care industry has never been greater than today in helping the global population address pressing issues related to aging, chronic disease, and promoting general wellness. Meeting these challenges, the sector has continuously demonstrated tremendous advancements in areas related to medical discoveries, health care management, and improving access to care. As shown in the graphic below, national annual healthcare spending is expected to continue to rise, increasing at a faster pace than the average annual GDP growth.

To provide investors exposure to what Guggenheim believes is an attractive investment opportunity in the medical industry, Guggenheim offers the Health Care Portfolio with core holdings diversified across several health care sub-industries.

National Health Care Spending Expected to Outpace GDP Growth³



³ CMS' National Health Expenditure Fact Sheet, 6.24.2025. Past performance is not a guarantee of future results. There is no guarantee that the trends and projections noted above will continue or come to fruition and they are subject to change.

PORTFOLIO HOLDINGS

Holdings, breakdown, and weightings are as of 7.16.2025 and subject to change.

Symbol	Company Name	Symbol	Company Name
Biotechnology 16.43%		Health Care Providers & Services 9.75%	
ABV	AbbVie, Inc.	ELV	Elevance Health, Inc.
BMRN	BioMarin Pharmaceutical, Inc.	GH	Guardant Health, Inc.
GILD	Gilead Sciences, Inc.	PRVA	Privia Health Group, Inc.
IONS	Ionis Pharmaceuticals, Inc.	CI	The Cigna Group
NBIX	Neurocrine Biosciences, Inc.	Life Sciences Tools & Services 8.57%	
REGN	Regeneron Pharmaceuticals, Inc.	DHR	Danaher Corporation
Health Care Equipment & Supplies 34.31%		TMO	Thermo Fisher Scientific, Inc.
ABT	Abbott Laboratories	WST	West Pharmaceutical Services, Inc.
ALGN	Align Technology, Inc.	Pharmaceuticals 30.94%	
BDX	Becton, Dickinson & Company	AXSM	Axsome Therapeutics, Inc.
BSX	Boston Scientific Corporation	BMJ	Bristol-Myers Squibb Company
DXCM	Dexcom, Inc.	LLY	Eli Lilly & Company
EW	Edwards Lifesciences Corporation	JAZZ	Jazz Pharmaceuticals PLC
ENOV	Enovis Corporation	JNJ	Johnson & Johnson
GEHC	GE Healthcare Technologies, Inc.	MRK	Merck & Company, Inc.
GMED	Globus Medical, Inc.	PFE	Pfizer, Inc.
MDT	Medtronic PLC	ZTS	Zoetis, Inc.
SYK	Stryker Corporation		

Health Care Portfolio, Series 39

PORTFOLIO SUMMARY

Inception Date	7.17.2025
Termination Date	7.19.2027
Initial Offer Price	\$10.00
Number of Issues	32
Historical Annual Dividend Distribution⁴	\$0.1225
Distributions	25th day of each month commencing on 8.25.2025, if any

SALES CHARGES AND ESTIMATED EXPENSES

The sales charges (S/C) and estimated expenses are based on a \$10 per unit offering price.

	Standard	Fee/Wrap ⁵
Deferred S/C ⁶	2.25%	-
Creation and Development (C&D) Fee	0.50%	0.50%
Total S/C	2.75%	0.50%
Estimated Organization Expenses ⁷	0.35%	0.35%
Estimated Annual Fund Operating Expenses ⁸	0.23%	0.23%

TICKETING INFORMATION - CUSIPS

Cash	40178K206
Reinvest	40178K214
Fee/Cash	40178K222
Fee/Reinvest	40178K230
Ticker	CHCRNX

⁴ The Historical Annual Dividend Distribution (HADD) is as of the day prior to trust deposit and subject to change. There is no guarantee the issuers of the securities included in the Trust will declare dividends or distributions in the future. The HADD of the securities included in the Trust is for illustrative purposes only and is not indicative of the Trust's distribution rate. The HADD is the weighted average of the trailing twelve-month distributions paid by the securities included in the portfolio and is reduced to account for the effects of fees and expenses, which will be incurred when investing in the Trust. The HADD will vary due to certain factors that may include, but are not limited to, a change in the dividends paid by issuers, a change in Trust expenses or the sale or maturity of securities in the portfolio. ⁵ Fee/Wrap-based accounts will not be assessed the deferred sales charge for eligible purchases and must purchase units with a Fee-based CUSIP. For unit prices other than \$10, percentage of the C&D fee will vary. ⁶ The deferred sales charge (DSC) is a fixed amount and will be deducted in monthly installments on the last business day commencing February 2026 and ending April 2026 or upon early redemption. For unit prices other than \$10, percentages of C&D fees, and DSCs will vary but in no event will the maximum sales charge (S/C) exceed the total S/C. Early redemption of units will still cause payment of the DSC. However, an initial sales charge, which is equal to the difference between the maximum S/C and the sum of any remaining deferred S/C charges and C&D, will be charged if the price paid for units exceeds \$10 per unit. ⁷ Estimated Organization Expenses are assessed on a fixed dollar amount per unit basis, therefore, actual organization costs may be more or less than estimates. For additional information on organizational costs and potential caps, please see the prospectus. ⁸ Trust operating expenses include fees for administration, bookkeeping, the trustee, sponsor, and evaluator. This expense also includes an estimated Trust operating expense based upon an estimated trust size. If the Trust does not reach or falls below the estimated size, the actual amount of the operating expenses may exceed the amount reflected. Please see "Fees and Expenses" in the Trusts prospectus for additional information.

The Health Care Portfolio, Series 39 is a Unit Investment Trust.

RISK CONSIDERATIONS: As with all investments, you may lose some or all of your investment in the Trust. No assurance can be given that the Trust's investment objective will be achieved.

The Trust also might not perform as well as you expect. This can happen for reasons such as these: • Securities prices can be volatile. The value of your investment may fall over time. Market values of the Trust's securities fluctuate in response to various factors affecting an issuer. Events such as war, terrorism, natural and environmental disasters and public health emergencies are impossible to predict and may adversely affect the economy which may negatively impact the performance of the Trust and the Trust's ability to achieve its investment objectives. • The Trust is concentrated in the health care sector and securities of pharmaceutical companies, health care equipment and supplies companies, as a result the factors that impact this sector and industries will have a greater effect on this Trust than on a more broadly diversified trust. • The Trust includes securities issued by mid-cap companies, which involve more

investment risk due to limited product lines, markets or financial resources and may be more vulnerable to adverse general market or economic developments. • The Trust may be susceptible to potential risks through breaches in cybersecurity. • The Trust is subject to risks arising from various operational factors and their service providers. Although the Trust seeks to reduce operational risks through controls and procedures, there is no way to completely protect against such risks. **Please see the Trust prospectus for more complete risk information.**

Unit Investment Trusts are fixed, not actively managed and should be considered as part of a long-term strategy. Investors should consider their ability to invest in successive portfolios, if available, at the applicable sales charge. UITs are subject to annual fund operating expenses in addition to the sales charge. Investors should consult an attorney or tax advisor regarding tax consequences associated with an investment from one series to the next, if available, and with the purchase or sale of units. Guggenheim Funds Distributors, LLC does not offer tax advice.

This material is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation.

Read the Trust's prospectus carefully before investing. It contains the Trust's investment objectives, risks, charges, expenses and other information, which should be considered carefully before investing. Obtain a prospectus at [GuggenheimInvestments.com](https://www.guggenheiminvestments.com).

Guggenheim Funds Distributors, LLC

Member FINRA/SIPC

7/2025 UIT-FCT-DHS-039 #65524